Fluxid is a drug owned by Ucb Inc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 09, 2018. Details of Fluxid's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6221392 | Rapidly dissolving robust dosage form |
Apr, 2018
(8 years ago) |
Expired
|
| US6024981 | Rapidly dissolving robust dosage form |
Apr, 2018
(8 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but
Fluxid is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Fluxid's family patents as well as insights into
ongoing legal events
on those patents.
Fluxid's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Fluxid:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Antihistamines in the Treatment of Irritable Bowel Syndrome With Diarrhea | University of Cincinnati | NA | WITHDRAWN
(Sep 1, 2026) | PHASE3 |
| A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Antacid in Healthy Adults | Pfizer | NA | NOT YET RECRUITING
(Sep 1, 2026) | PHASE1 |
| Study on the Effect of Famotidine on Pharmacokinetics of Taletrectinib | Nuvation Bio Inc. | NA | NOT YET RECRUITING
(Jul 1, 2026) | PHASE1 |
| Famotidine vs Placebo for the Treatment of Non-Hospitalized Adults With COVID-19 | Northwell Health | NA | COMPLETED
(Jun 1, 2026) | PHASE2 |
| A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors | Epkin | NA | RECRUITING
(Jun 1, 2026) | PHASE1 |
| A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants | Bristol-Myers Squibb | NA | COMPLETED
(May 1, 2026) | PHASE1 |
Generic Launch
Generic Release Date:
Fluxid's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 09, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Fluxid Generic API suppliers:
Famotidine is the generic name for the brand Fluxid. 54 different companies have already filed for the generic of Fluxid, with Annora Pharma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Fluxid's generic
Alternative Brands for Fluxid
There are several other brand drugs using the same active ingredient (Famotidine) as Fluxid. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Horizon |
| ||
| J And J Consumer Inc |
| ||
| Kenvue Brands |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Famotidine, Fluxid's active ingredient. Check the complete list of approved generic manufacturers for Fluxid
About Fluxid
Fluxid is a drug owned by Ucb Inc. Fluxid uses Famotidine as an active ingredient. Fluxid was launched by Ucb in 2004.
Approval Date:
Fluxid was approved by FDA for market use on 24 September, 2004.
Active Ingredient:
Fluxid uses Famotidine as the active ingredient. Check out other Drugs and Companies using Famotidine ingredient
Dosage:
Fluxid is available in tablet, orally disintegrating form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 20MG | TABLET, ORALLY DISINTEGRATING | Discontinued | ORAL |
| 40MG | TABLET, ORALLY DISINTEGRATING | Discontinued | ORAL |